New York Asbestos Exposure Lawyer Encouraged By Experimental Drug That Targets Mesothelioma Tumors
New York, NY, July 19, 2012 — New York asbestos exposure attorney Joseph W. Belluck today hailed reports of small progress in the effort to develop a new type of medication that could potentially benefit victims of mesothelioma, a deadly cancer caused by exposure to asbestos fibers.
“Mesothelioma is such a serious disease, and the prognosis for so many victims is so dire, that it is welcome news whenever we hear about new developments in cancer treatments that could in the future help mesothelioma patients live longer and better,” said Belluck, a partner in Belluck & Fox, LLP, a New York law firm that has developed a national reputation for representing victims of asbestos exposure.
Belluck was referring to news delivered in a recent Mesothelioma Applied Research Foundation teleconference regarding promising developments in the study of Mesothelioma Applied Research Foundation. One of the lead researchers, Dr. Raffit Hassan of the National Cancer Institute, discussed his team’s trial of a new line of drugs that uses the protein mesothelin to target mesothelioma.
Mesothelin is found throughout the body. Tumors such as those associated with mesothelioma secrete large amounts of the protein. This makes it an ideal way to target the tumors.
The experimental drug, known as Morab 009, is designed to use mesothelin to seek out and bind to cancer cells, and then inject an immunotoxin into the tumor to kill it, according to Dr. Hassan.
While Dr. Hassan said that the clinical trials could eventually result in a new drug to treat both pleural and peritoneal mesothelioma, he stressed that further studies are required to show that the medication is effective and produces better results than chemotherapy alone. He said the next step will likely be a randomized clinical study.
The first two phases of the drug’s clinical testing have been completed. The results were scheduled to be presented at an oncology conference this summer, according to the Meso Foundation. The drug remains in the trial stage and has not received approval from the U.S. Food and Drug Administration.
Dr. Hassan, who has been researching mesothelin-based drugs for 15 years, did not provide details about the outcome of the clinical trials during the teleconference, but he did say that there were some “exciting results.” He also said that patients appear to tolerate the medication well and that side effects are not severe.
Belluck, the New York mesothelioma lawyer, said he is hopeful that the experimental drug could one day help cancer patients like the clients he represents in personal injury lawsuits stemming from their exposure to cancer-causing asbestos.
“We must support the efforts of the National Cancer Institute and other organizations that are working hard to develop new innovations in the treatment of mesothelioma,” Belluck said. “In my legal practice, I have seen time and again how the rare but devastating disease of mesothelioma can destroy a person’s life. Victims deserve the best medical treatment science can provide.”
The firm’s New York City office is located at 546 Fifth Ave., 4th Floor, New York, NY 10036 (local phone number (212) 681-1575). For more information, contact the firm at (877) 637-6843 or through its online contact form.